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Abstract: Teixobactin, a recently discovered depsipeptide that binds 
to bacterial lipid II and lipid III, provides a promising molecular 
scaffold for the design of new antimicrobials. Herein, we describe the 
synthesis and antimicrobial evaluation of systematically modified 
teixobactin analogues. The replacement of Ile11 residue with aliphatic 
isosteres, the modification of the guanidino group at residue 10 and 
the introduction of a rigidifying residue, dehydroamino acid into the 
macrocyclic ring generated useful structure-activity information. 
Extensive antimicrobial susceptibility assessment against a panel of 
clinically relevant Staphylococcus aureus and Propionibacterium 
acnes led to the identification of a new lead compound, 
[Arg(Me)10,Nle11]teixobactin 63, with excellent bactericidal activity 
(MIC 2–4 μg/mL). Significantly, the antimicrobial activity of several of 
the teixobactin analogues against the pathogenic Gram-negative 
Pseudomonas aeruginosa was ‘restored’ when combined with sub-
MIC concentration of the outer membrane-disruptive antibiotic, 
colistin. The antimicrobial effectiveness of [Tfn10,Nle11]teixobactin 66 
(32 μg/mL)-colistin (2 μg/mL; 0.5x MIC) combination against P. 
aeruginosa PAO1 reveals, for the first time, an alternative 
therapeutic option in the treatment of Gram-negative infections. 
Introduction 
Life-saving antibiotics are rapidly losing the race against the 
development of bacterial resistance to most, if not all, antibiotics. 
The resultant health and financial implications have spurred the 
deployment of antimicrobial stewardship programmes across the 
globe to ensure evidence-based prescribing of antibiotics that 
are still effective.[1–3] Meanwhile, scientists are working hand-in-
hand to tackle the resistance crisis through drug discovery and 
development initiatives.  
Natural antimicrobial peptides serve as invaluable 
molecular scaffolds for the development of the next generation 
of antimicrobial therapeutics. The recently discovered 
depsipeptide, teixobactin 1 (Figure 1), has great potential as a 
lead compound due to its favourable potency against many 
Gram-positive pathogens.[4] Among them, teixobactin has 
demonstrated excellent bactericidal activity against methicillin-
resistant Staphylococcus aureus (MRSA) which is associated 
with a wide range of infections in both the community (e.g. 
cellulitis, abscesses) and the hospital settings (e.g. bacteraemia, 
pneumonia).[4–6] Vancomycin is currently the last line of defence 
against MRSA infections but strains with reduced susceptibility 
to this antibiotic have surfaced.[7–10] Teixobactin offers a potential 
solution to this predicament since it remains effective against 
MRSA, as well as vancomycin-intermediate S. aureus (VISA) 
due to its unique mode of action.[4] It has been shown to 
synergistically block the biosyntheses of peptidoglycan and 
teichoic acid, thereby resulting in a weakened cell wall and 
autolysin-mediated cell lysis.[4,11] 
Teixobactin 1 is also a potent antimicrobial against another 
human skin commensal, Propionibacterium acnes.[4] This Gram-
positive anaerobe is commonly associated with acnes 
vulgaris.[12] In recent years, however, it is increasingly 
recognised as an opportunistic pathogen that can cause 
invasive infections, especially those associated with medical 
implants.[13,14] There have been several reports on the isolation 
of P. acnes from prosthetic joints, cardiovascular devices and 
ophthalmic implants.[14–18] To aggravate matters, the widespread 
use of antibiotics to treat acne vulgaris has led to the emergence 
of P. acnes strains that are resistant to numerous antibiotics, 
including the macrolides, tetracycline and metronidazole.[13,19–22] 
The need for novel antimicrobials is therefore more pressing 
than ever. It is hoped that teixobactin and its analogues may 
serve as a timely solution to this clinically important pathogen.  
Figure 1. Structure of teixobactin 1 and the four sites (blue) of modification 
presented in this work. 
 
Teixobactin 1, comprised of a 13-membered depsipeptide 
core and a tethered linear heptapeptide, offers multiple sites for 
synthetic modifications to improve its potency and efficacy. In 
less than three years since its discovery, more than a hundred 
analogues have been synthesized by various research groups in 
the hope of elucidating its structure-activity relationships 
(SARs).[23–37] The biological activities of these analogues and the 
different synthetic strategies reported have been 
comprehensively reviewed.[38,39] X-ray crystallographic, 
molecular dynamic and NMR structural studies have also been 
conducted to construct possible binding models of the native 
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peptide and its analogues.[26,27,40] Additionally, in a recent mini-
review, we provided an insight into the structural similarities of 
teixobactin with other lipid II inhibitors.[41] Together, these 
resources provide tremendous information that could aid the 
design of optimised analogues.  
Early synthetic endeavours focused primarily on the 
exocyclic tail and the backbone stereochemistry of the native 
peptide. The replacement of any D-amino acid residues with its 
L-counterparts abolished activity, suggesting a significant 
contribution of these residues for the optimal conformation of 
teixobactin.[25,26,30] Yang et al. further demonstrated the 
importance of the N-terminal tail as the removal of the first five 
residues detrimentally affected antimicrobial potency.[24] 
Teixobactin appears to bind to the pyrophosphate and N-
acetylmuramic acid amino sugar of lipid II. As such, its cyclic 
ring is believed to act as the main site of recognition.[4] With 
these considerations in mind, we have developed a series of 
analogues with modifications mainly on the macrocyclic core to 
examine the significance of hydrophobicity at position 11, the 
cationic feature of the guanidino group at position 10, and the 
effect of introducing conformational rigidity at position 9. The N-
Me-D-Phe1 was also replaced with D-Trp in an attempt to 
investigate the contribution of the phenyl group.  
Apart from replacing the Ile residue at position 11 with 
readily available aliphatic isosteres, we sought to investigate the 
effect of introducing fluorine atoms and unsaturated side-chain 
at this position. Thus, Fmoc-(S)-6,6,6-trifluoronorleucine-OH 
(Fmoc-Tfn-OH) and Fmoc-(S)-homoallylglycine-OH (Fmoc-Hag-
OH) were synthesized and their preparation will be discussed 
prior to the synthesis of the teixobactin analogues. All analogues 
were extensively evaluated for their antimicrobial activity against 
both S. aureus and P. acnes. Thus far, most biological 
assessments of reported teixobactin analogues are focused on 
S. aureus and only the activity of the native peptide is known 
against P. acnes. Herein, we report detailed antimicrobial activity 
of teixobactin analogues against several P. acnes strains. 
Although teixobactin and analogues thereof are considered 
inactive against Gram-negative bacteria (MIC >256 μg/mL), the 
effect of using teixobactin analogues in combination with colistin 
was also investigated against the Gram-negative pathogen 
Pseudomonas aeruginosa.  
Results and Discussion 
Synthesis of Fmoc-(S)-6,6,6-trifluoronorleucine-OH and 
Fmoc-(S)-homoallylglycine-OH  
 
An operationally simple and cost-effective approach for the 
asymmetric synthesis of Fmoc-Tfn-OH (S)-7  and Fmoc-Hag-OH 
(S)-9 is by alkylation of an achiral auxiliary reagent Ni(II)-glycine 
Schiff base (S)-5.[42,43] The Ni(II)-complex (S)-5 was synthesized 
in large scale in three straightforward steps (Scheme 1). The 
coordination of Ni(II) ion to the glycine greatly increased the 
acidity of the α-proton, enabling subsequent rapid alkylation with 
an alkyl halide.[42] 
 
 
 
 
 
 
 
 
 
Scheme 1. An optimized synthesis of Ni(II)-Gly-(S)-2-[N-(N-
benzylprolyl)amino]-benzophenone (BPB). 
 
Thus, using the protocol developed by Belokon et al., the 
first step in the synthesis progressed smoothly to give N-
benzylated L-proline (S)-(3) in high yield.[43] Although the 
condensation between (S)-(3) and 2-aminobenzophenone did 
not proceed to completion, a reasonable yield of 45–60 % was 
obtained. To our dismay, the use of KOH in the final step, i.e. 
the transformation of (S)-4 to (S)-5, gave a disappointing 50 % 
recovery of (S)-5 after three recrystallizations. A review of the 
literature indicated that K2CO3 was previously employed by 
Soloshonok and co-workers to prepare a closely related Schiff 
base,[44] thereby suggesting that this alternative base could be 
more effective for synthesizing (S)-5. Gratifyingly, K2CO3 (20 
equiv.) drove the final reaction step to completion within an hour 
and (S)-5 was recrystallized from MeOH/H2O in >85 % yield.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. An optimised synthesis of Fmoc-6,6,6-trifluoronorleucine-OH. 
 
Having successfully prepared the Ni(II)-Schiff base (S)-5, 
we then sought to optimise the alkylation of the complex with 
1,1,1-trifluoro-4-iodobutane (Scheme 2). Wang et al. have 
previously reported a high diastereoselectivity (97%) was 
achieved with only 1.1 equiv. of NaOH.[45] We have, however, 
obtained contradictory results. Although the rate of reaction 
increased with an increased amount of NaOH, the 
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diastereoselectivity between (S,S)-6 and (S,R)-6 was 
disappointingly low (Table 1). It has been shown in other studies 
that when a monoalkylated complex is subjected to 
epimerisation under basic condition, thermodynamic control 
would dominate and eventually drives the equilibrium towards 
the favoured (S,S)-epimer.[46–48] Thus, a mixture of the (S,S)- 
and (S,R)-alkylated complex 6 was partially purified in a reaction 
work-up, and subsequently treated with K2CO3 in MeOH at 
60 °C (Table 1, entry 3). A satisfactory diastereomeric ratio of 
97:3 was obtained. In a series of pilot experiments, the addition 
of K2CO3 directly into the DMF reaction mixture at 60 °C did not 
afford the desirable level of diastereoselectivity whereas 
increasing the amount of NaOH led to the formation of other by-
products. As such, the rate of epimerization and the shift of 
equilibrium towards the (S,S)-epimer seemed to be highly 
dependent on the use of a polar protic solvent.  
 
 
Table 1. Conditions investigated for the alkylation of (S)-5 with 1,1,1-trifluoro-4-
iodobutane.[a] 
Entry Condition Total 
reaction time 
(h) 
(S,S):(S,R)[b] Yield (%) 
1 NaOH (2 equiv.), DMF, r.t. 1.5 77/23 75 
2 NaOH (5 equiv.), DMF, r.t. 0.5 77/23 61 
3 NaOH (5 equiv.), DMF, r.t. 
followed by K2CO3 (5 equiv.), 
MeOH, 60 °C 
2.5 97/3 73 
[a] Reactions were performed using 0.40 mmol (S)-5 and 0.44 mmol alkyl halide. 
[b] Diastereomeric ratio determined using analytical RP-HPLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. The synthetic route to Fmoc-homoallylglycine-OH. 
 
Finally, the de-assembly of (S,S)-6 to yield the desired amino 
acid was achieved by microwave-assisted acid-mediated 
hydrolysis. Without further purification, the released amino acid 
was N-protected with a Fmoc group. Following a simple work-up, 
trituration with hexane afforded sufficiently pure Fmoc-Tfn-OH 
(S)-7 for incorporation into the macrocycle of teixobactin. Fmoc-
Hag-OH (S)-9 was prepared under similar conditions by 
alkylating Schiff base (S)-5 with 4-bromo-but-1-ene (Scheme 3). 
These Fmoc-protected amino acids were used in the synthesis 
of our teixobactin analogues.  
 
Synthesis of teixobactin analogues 
 
The substitution of the L-allo-enduracididine10 in teixobactin 1 
with arginine has been shown to retain appreciable activity.[23–25] 
Hence, (Arg10)teixobactin 55 was initially prepared (Scheme 4) 
to serve as the positive control in our microbiological evaluation. 
The robust synthetic method reported by Yang et al. was 
adapted with several adjustments.[24] This synthetic strategy 
enabled the use of the resin-anchored linear decapeptide 16 as 
a common intermediate for subsequent on-resin esterification 
with different protected amino acid building blocks, thus 
providing an expedient access to teixobactin analogues 57–62.  
The 2-chlorotrityl chloride resin was used as the polymer 
support as it allowed the liberation of the branched peptide by 
mild acidolysis while retaining the side-chain protecting groups. 
In the synthesis of (Arg10)teixobactin 55, the resin was first 
loaded with Fmoc-Arg(Pbf)-OH and the peptide chain was 
elongated stepwise by acylation with Fmoc-amino acids that 
were pre-activated by HATU (1-[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate) 
in the presence of iPr2EtN. In order to minimise steric hindrance 
effects, Fmoc-D-Thr-OH and Fmoc-D-Gln-OH were used without 
side-chain protecting groups and no significant problems were 
observed during their couplings. 
The esterification of the D-Thr residue in intermediate 16 
was then carried out with a pre-formed symmetrical anhydride of 
Fmoc-Ile-OH. It was found that the esterification step required 
up to four repeated couplings, each requiring overnight (15–18 
h) exposure, in order to achieve approximately 50 % 
transformation as monitored by RP-HPLC. The long reaction 
time could be attributed to the steric bulk of the Ile side-chain 
and the entrenched hydroxyl group of the D-Thr residue. In 
contrast, greater than 70 % O-acylation of the D-Thr residue was 
achieved with Nle, Nva, Abu and Ala as the acylating amino 
acids (analogues 57–60), further corroborating the significance 
of steric effects. Following Fmoc-deprotection, the branched 
peptide 25 was cleaved from the resin in preparation for 
solution-phase intramolecular cyclisation between the Arg10 and 
Ile11 residues.  
The use of (1-cyano-2-ethoxy-2-oxoethylidenamino-
oxy)dimethylamino-morpholino-carbenium hexafluorophosphate 
(COMU) as the carboxy-activating reagent enabled the 
cyclisation to be visually monitored through colour changes.[49,50] 
Upon addition of base, the solution changed from yellowish-
orange to colourless in under an hour and the reaction was 
completed within 2 h. Global side-chain deprotection by 
acidolysis of the macrocyclic intermediate, followed by RP-HPLC 
purification and lyophilisation afforded 55 as a white solid. 
All the other analogues were similarly prepared by 
replacing Ile11 with various aliphatic residues, including the use 
of the synthesized Fmoc-Tfn-OH and Fmoc-Hag-OH (57–62), 
Arg10 with several arginine derivatives and Tfn (63–66), Ala9 with 
Abu and Z-dehydrobutyrine (Dhb) (67–68), and finally, N-Me-D-
Phe1 with D-Trp (69) (Figure 2). 
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Scheme 4. Synthetic route for the preparation of teixobactin analogues. The synthesis of branched peptides 25–39 were performed solely on a polymer support 
(2-chlorotrityl chloride resin) using a 9-fluorenylmethyloxycarbonyl (Fmoc/tBu) strategy. The cleaved peptides 40–54 were then subjected to solution-phase 
macrolactamisation.  
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Figure 2. The chemical structures of teixobactin analogues synthesized for antimicrobial evaluation. 
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Broth microdilution and growth inhibition assays 
Minimal inhibitory concentration (MIC) is the most commonly 
used parameter to define in vitro antimicrobial susceptibility. It is 
defined as the lowest concentration of a compound that inhibits 
visible growth. Using the broth microdilution method outlined in 
the Clinical and Laboratory Standards Institute (CLSI) 
guidelines[51], the MIC values of our teixobactin analogues 
against five prominent isolates of S. aureus from different clinical 
settings and with varying antibiotic sensitivity were obtained. 
Among them, S. aureus USA300 JE2 is particularly virulent due 
to the expression of Panton-Valentine Leukocidin (PVL). In fact, 
the incidence of skin and soft tissue infections caused by S. 
aureus has increased substantially since the late 1990s, which is 
largely driven by the emergence of the USA300 clone.[52,53] The 
MIC was also determined for three P. acnes strains and the 
Gram-negative Pseudomonas aeruginosa PAO1. A summary 
description of the bacteria strains used in this study is provided 
in Table 2. 
Since MIC is determined at a fixed incubation time-point 
(typically 16 h or 24 h), detailed information on how bacterial 
growth rate is affected by antimicrobials at different 
concentrations is unavailable.[65] Hence, a sensitive assay that 
involved the generation of growth curves was concurrently used 
to evaluate the synthesized teixobactin analogues.  
S. aureus SH1000, a fully sequenced strain that is 
representative of the species, was used as the test 
microorganism in our growth inhibition assay. The starting 
bacterial concentration was adjusted to give approximately 106 
colony forming units/mL (CFU/mL) in each well of a 96-well 
microtitre plate. Following treatment with different concentrations 
of the compounds, bacterial growth was monitored for 20 h by 
measuring the optical density at 600 nm. The normalized 
percentage growth at 13 h was then used to construct a dose-
response curve in order to determine the concentration at which 
50 % of the bacterial growth was inhibited (IC50). As illustration, 
the dose-response curves of two analogues, 
(Arg10,Nle11)teixobactin 57 (IC50 = 7.38 ± 0.09 μM) and 
(Arg10,Ala11)teixobactin 60 (IC50 >100 μM), are shown in Figure 
3; detailed growth curves and their corresponding dose-
response curves are provided in the Supporting Information (p. 
S37–S40).  
The sigmoidal dose-response curves of all active 
analogues showed a sharp drop in percentage growth as the 
concentration of the test compounds were increased. This was 
also observed with vancomycin, a well-established lipid II 
inhibitor which was used as the positive control. This 
phenomenon where a small change in concentration causes 
substantial growth inhibition appeared to be a common attribute 
of lipid II and/or lipid III binders. In addition to a measurement of 
potency, the IC50 values (Table 3) provided useful and invaluable 
SAR information on the effect of subtle changes in the chemical 
composition of our teixobactin analogues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Dose-response curves of analogues 57 and 60 against S. aureus 
SH1000. Three independent experiments were conducted, with vancomycin 
(IC50 = 0.45 ± 0.13 μM) as the positive control.  
 
 
Table 2. Bacterial strains used for antimicrobial susceptibility testing of 
teixobactin analogues. 
Organism Description Reference 
S. aureus   
SH1000 S. aureus 8325-4 strain with repaired rsbU gene [54] 
Newman Clinical MSSA isolate with fully sequenced genome 
and lacks in antibiotic resistant genes 
[55,56] 
PM64 Healthcare-associated MRSA, isolate of the 
epidemic MRSA type 16 clonal group (EMRSA-16) 
[57] 
USA300 JE2 Community-acquired MRSA USA300 LAC cured of 
three plasmids 
[58] 
Mu50 Vancomycin-intermediate resistant strain (VISA) 
with thickened cell walls 
[8,9,59] 
P. acnes   
ATCC 11828 Representative strain of the type II phylotype [60,61] 
ATCC 6919 Representative strain of the type IA1 phylotype [62] 
Asn12 Representative strain of type III phylotype isolated 
from intervertebral disc material  
[63] 
P. aeruginosa   
PAO1 Gram-negative, wild-type laboratory strain, 
Nottingham sub-line  
[64] 
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The (Arg10,Nle11)teixobactin (57) was also tested using the 
same methodology against P. acnes ATCC 11828 (Figure 4). 
Unlike S. aureus, the anaerobe P. acnes showed a more 
gradual decrease in growth with increasing concentrations of the 
test compound. This distinct dose-response pattern may be due 
to the slow-growing nature of the bacteria and/or the difference 
in its cell wall composition compared to other Gram-positives.[13] 
In future, further work will be performed to establish the lipid 
contents of the cell wall of P. acnes in order to shed light on the 
binding efficacy of teixobactin analogues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Dose-response curves of analogue 57 against P. acnes ATCC 
11828 (IC50 = 3.56 ± 0.23 μM). Three independent trials were conducted with 
vancomycin (IC50 = 0.29 ± 0.03 μM) as the positive control.  
 
Both arginine and lysine have been used as a substitute 
for L-allo-enduracididine at position 10. Yang et al. reported that 
(Lys10)teixobactin showed a 2- to 4-fold lower MIC values than 
(Arg10)teixobactin against specific strains of Staphylococcus 
epidermidis, Streptococcus salivarus, Enterococcus durans and 
Bacillus subtilis.[24] A similar result against MRSA ATCC 33591 
has recently been observed by Singh and co-workers.[37] 
However, based on the MIC values, we observed that the 
(Lys10)teixobactin was in fact consistently 2-fold less potent 
compared to (Arg10)teixobactin across the S. aureus strains 
tested; the IC50 data similarly reported a 2.2-fold loss of activity. 
Since (Arg10)teixobactin showed a better antibacterial profile 
here, Arg was maintained at this position in analogues 57 to 62 
in our initial SAR study.  
The Ile11 was initially replaced with its aliphatic isostere, 
Nle. The resultant (Arg10,Nle11)teixobactin 57 (IC50 = 7.38 ± 0.09 
μM) was found to have comparable potency, if not slightly better 
than (Arg10)teixobactin 55 (IC50 = 7.96 ± 0.36 μM) in inhibiting the 
growth of S. aureus SH1000. Additionally, both analogues 
showed the same MIC of 8 μg/mL against three different strains 
of S. aureus. It was surprising to observe that 
(Arg10,Nle11)teixobactin was 2-fold more potent against MRSA 
PM64 but 2-fold less active against VISA Mu50. Nevertheless, 
the overall results suggest that the flexible linear aliphatic chain 
of Nle seemed to confer similar hydrophobic interactions as the 
branched chain of Ile. Decreasing the alkyl chain length, 
however, has a negative impact. There was an increasing 
reduction in antimicrobial potency with the replacement of Nle 
with Nva and Abu (compounds 58 and 59) followed by a 
complete loss of activity when Ala was installed (compound 60). 
This indicates that a minimum of four carbons are necessary for 
optimal hydrophobic interactions. The importance of a non-polar 
group at position 11 was also evident in previous studies which 
showed that the substitution of Ile with a polar residue, such as 
Lys, abolished antibacterial activity.[27,31] 
Having identified Nle as a beneficial substitute of Ile, we 
next investigated the effects of introducing fluorine atoms and an 
unsaturated functional group in the hydrocarbon side-chain. It is 
hypothesised that the replacement of the terminal methyl in Nle 
with a trifluoromethyl moiety could provide the extra 
hydrophobicity needed for effective binding. However, the 
antimicrobial potency against S. aureus SH1000 dropped by 
almost 4.0-fold when Nle was replaced with Tfn in compound 61. 
The MIC values of (Arg10,Tfn11)teixobactin 61 against the other S. 
aureus strains were also observed to be 2- to 4-fold higher 
compared to (Arg10,Nle11)teixobactin 57. The electronegativity of 
the fluorine atoms appeared to detrimentally affect the 
interaction of the (Arg10,Tfn11)-analogue 61 with its molecular 
targets. Alternatively, the steric effect from the bulkier CF3 
moiety might have caused the decrease in activity. Further work 
could be carried out by synthesizing a shorter trifluoromethylene 
analogue since the -CF3 is considered an isosteric replacement 
of an ethyl moiety.[66–68] A similar increase in both IC50 and MIC 
was observed when a terminal alkenic bond was introduced 
(compound 62). Nle was therefore chosen as the optimal 
residue at this position for the subsequent six analogues 63–68, 
in which the effect of replacing the guanidine moiety in Arg10 was 
investigated. The less sterically demanding Nle additionally 
provided a synthetic advantage in the esterification step 
compared to Ile.  
The cationic nature of L-allo-enduracididine10 in the native 
peptide is thought to be crucial in the electrostatic interaction 
with the negatively-charged pyrophosphate moiety in lipid II.[4] In 
this unusual amino acid, the terminal NH group of its guanidine 
moiety is connected to the γ-carbon to afford a heterocyclic 
structure. As such, it was envisaged that additional methyl 
group(s) on the guanidine in the side-chain would closely mimic 
the natural interaction of teixobactin with lipid II. Gratifyingly, 
compared to (Arg10,Nle11)-analogue 57, the 
[Arg(Me)10,Nle11]teixobactin 63 displayed a 2-fold increase in 
antimicrobial potency against several S. aureus strains (4-fold in 
S. aureus Mu50) when evaluated using the IC50 and MIC values. 
Evich et al. has shown that the pKa of the guanidino group of Arg 
is not significantly altered by methylation.[69] Hence, the increase 
in hydrophobicity rather than basicity resulting from the NG-
methylation has contributed to a greater binding affinity. On the 
other hand, the asymmetric and symmetric NG-dimethylated 
arginine analogues, 64 and 65, respectively showed 3.4- and 
2.4-fold reduction in potency (IC50) compared to the 
corresponding Arg analogue 57. The introduction of the second 
methyl group appeared to be detrimental, possibly due to 
disruption of potential hydrogen bond(s) or significant steric 
hindrance.[69] These results are consistent with other studies that 
showed a lack of activity when the guanidino group was tetra-
alkylated.[35]  
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   Table 3. The antibacterial activity of teixobactin analogues and several antibiotics. 
 [a] IC50 values were expressed as the mean ± SD of three independent growth inhibition assay; n.d. = not determined. [b] MIC determined by broth microdilution 
performed in triplicates according to CLSI guidelines. [c] MIC values of teixobactin were obtained from literature; Nle = norleucine; Nva = norvaline; Abu = 
aminobutyric acid; Tfn = trifluoronorleucine; Hag = homoallylglycine; Arg(Me) = monomethylarginine; ADMA = asymmetric dimethylarginine; SDMA = symmetric 
dimethylarginine; Dhb = dehydrobutyrine.  
 
 
Compound 
IC50 (μM) 
against 
S. aureus 
SH1000[a] 
Minimum inhibitory concentration (μg/mL)[b] 
S. aureus  P. acnes P. aeruginosa 
SH1000 Newman USA300 JE2 PM64 Mu50  
ATCC 
11828 
ATCC 
6919 Asn12 PAO1 
(Arg10)teixobactin 55 7.96 ± 0.36 8 8 8 8 8  4 4 4 >256 
(Lys10)teixobactin 56 17.43 ± 2.31 16 16 16 16 16  8 8 8 >256 
(Arg10,Nle11)teixobactin 57 7.38 ± 0.09 8 8 8 4 16  4 4 4 >256 
(Arg10,Nva11)teixobactin 58 8.53 ± 0.37 8 8 16 8 16  8 8 4 >256 
(Arg10,Abu11)teixobactin 59 14.74 ± 0.25 16 16 16 16 32  8 8 8 >256 
(Arg10,Ala11)teixobactin 60 > 100 >32 >32 >32 >32 >32  32 >32 32 >256 
(Arg10,Tfn11)teixobactin 61 29.16 ± 1.51 32 32 32 16 32  16 32 32 >256 
(Arg10,Hag11)teixobactin 62 28.55 ± 0.24 32 32 32 32 32  16 32 32 >256 
(Arg(Me)10,Nle11)teixobactin 63 3.84 ± 0.26 4 4 4 2 4  2 4 2 >256 
(ADMA10,Nle11)teixobactin 64 24.83 ± 4.47 16 32 32 16 32  8 8 8 >256 
(SDMA10,Nle11)teixobactin 65 17.82 ± 3.42 16 16 16 16 32  8 8 8 >256 
(Tfn10,Nle11)teixobactin 66 8.02 ± 0.26 8 8 8 8 8  8 4 4 >256 
(Abu9,Arg10,Nle11)teixobactin 67 7.52 ± 0.24 8 8 8 8 8  4 4 4 >256 
(Dhb9,Arg10,Nle11)teixobactin 68 25.69 ± 4.57 32 32 32 16 32  16 16 16 >256 
(D-Trp1,Arg10)teixobactin 69 > 100 >32 >32 >32 >32 >32  >32 >32 >32 >256 
Teixobactin[c] - - - 0.5[11] - -  - 0.08[4] - >100[4] 
Meropenem n.d. <0.0625 <0.0625 <0.0625 16 n.d.  n.d. n.d. n.d. 8 
Vancomycin 0.45 ± 0.13 1 0.5 0.5 0.25 4  1 2 1 >256 
Colistin n.d. n.d. n.d. n.d. n.d. n.d.  n.d. n.d. n.d. 4 
Tunicamycin n.d. n.d. n.d. 8 n.d. n.d.  n.d. n.d. n.d. n.d. 
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Given the likely favourable electronic and hydrophobic 
properties of our synthesized trifluoromethyl-containing amino 
acid, the (Tfn10,Nle11)teixobactin 66 was synthesized and found 
to be only marginally less active than (Arg10,Nle11)teixobactin 57 
(IC50 8.02 ± 0.26 cf 7.38 ± 0.09 μM). This result reveals that 
position 10 is a good location for the introduction of other 
fluorinated hydrocarbon amino acids. In fact, Chen et al. 
reported that (Ala10)teixobactin unexpectedly retained 
considerable activity against S. aureus; it was proposed that a 
positively-charged residue is not essential at position 10.[34]  
The role of the Ala9 residue is not fully known except that it 
could be replaced with polar amino acids, such as Lys or 
Orn.[27,29,31,35] We observed that replacement of the methyl group 
with an ethyl moiety did not significantly change the antimicrobial 
activity since (Abu9,Arg10,Nle11)teixobactin 67 and 
(Arg10,Nle11)teixobactin 57 are essentially equipotent against the 
tested S. aureus strains. Subsequently, the possibility of 
improving the conformational characteristics of the peptide 
through the installation of an α,β-dehydroamino acid was 
investigated. The alkenic amino acid residue is known to rigidify 
the backbone of macrocyclic rings and could lead to a desirable 
peptide conformation that enhances binding to its target(s).[70]  Z-
Dhb was chosen as the test residue due to its natural 
abundance in antimicrobial peptides, including the lipid II-binder 
nisin.[71,72] However, compared to the corresponding Abu-
containing analogue 67, the potency of 
(Dhb9,Arg10,Nle11)teixobactin 68 was decreased by 3.4-fold; 
using the MIC values, a reduction of 2- to 4-fold in activity was 
observed against all the tested S. aureus strains.  A similar 
result was found by Albericio and co-workers when 4-
aminoproline was introduced at position 10 to constrict the 
macrocyclic ring.[35] Collectively, these results showed that 
conformational restriction has an unfavourable effect on target 
binding. 
Meanwhile, hydrophobicity was previously found to play a 
significant role at position 1. Although the removal of the N-
methyl group from N-Me-D-Phe1 has a minimal effect on potency, 
activity was lost when Wu et al. replaced D-Phe with D-Tyr.[28] 
The same observation was obtained with analogue 69, in which 
the phenyl was substituted with an indole moiety; our (D-
Trp1,Arg10)-analogue 69 is essentially inactive. 
The treatment of MRSA infection is increasingly difficult 
due to the co-emergence of VISA strains. It is therefore not 
surprising that the MIC of vancomycin is increased by 4- to 16-
fold when tested against VISA Mu50 (Table 3). This is attributed 
to thicker peptidoglycan layers and a lower degree of cross-
linking that exposes more of the D-alanyl-D-alanine binding site 
of vancomycin.[8,9] A large proportion of the vancomycin 
molecules are consequently trapped or titrated out by the mature 
peptidoglycan, preventing them from reaching their vital targets 
near the cytoplasmic membrane.[9] In contrast, most of the 
teixobactin analogues tested showed the same MIC across all 
the S. aureus strains, including Mu50. Hence, these teixobactin 
analogues, similar to the parent teixobactin, are unaffected by 
the thicker peptidoglycan layers in the VISA strains.[11] On a side 
note, studies have suggested the addition of a surfactant in the 
broth microdilution assay to prevent possible adsorption of the 
peptide compounds to the plastic wall of the 96-well 
plate.[4,11,73,74] However, no difference in MIC was observed for 
[Arg(Me)10,Nle11]teixobactin 63 in the presence of 0.002 % or 
0.1 % Tween 80. 
We next evaluated the antimicrobial utility of our 
teixobactin analogues against the opportunistic pathogen P. 
acnes. The majority of the analogues showed a 2-fold higher 
potency against the three P. acnes strains tested compared to S. 
aureus (Table 3). In the broth microdilution assay, the bacteria 
inoculum for P. acnes was approximately 100-fold higher than S. 
aureus. As such, the MIC values of the teixobactin analogues 
are likely to be considerably lower if a similar inoculum size was 
used. Overall, the results are in agreement with teixobactin 
which showed a 3-fold higher potency against P. acnes 
compared to S. aureus.[4] It is worth highlighting that the MIC of 
our most potent analogue, [Arg(Me)10,Nle11]teixobactin (63), is 
comparable to that of vancomycin. These results demonstrate 
the promising application of our teixobactin analogue against the 
emerging pathogenic bacterium P. acnes. 
 
Time-kill assay to establish bactericidal activity against S. 
aureus and P. acnes 
 
 
Figure 5. Time-kill curves of S. aureus USA300 JE2 treated with (a) 4x MIC 
[Arg(Me)10,Nle11]teixobactin 63 or 4x MIC vancomycin in the presence and 
absence of tunicamycin (0.4 μg/mL) and (b) 10x MIC 63 or 10x MIC 
vancomycin. Data are presented as the mean log10 viable counts (CFU/mL) ± 
SD from two independent experiments.  
 
Teixobactin has been shown to possess excellent bactericidal 
activity against S. aureus.[4,11] Although both IC50 and MIC 
values are good indicator of potency, it remains unknown if our 
teixobactin analogues are bacteriostatic or bactericidal.[65] Hence, 
the killing kinetics of our most potent analogue, 
[Arg(Me)10,Nle11]teixobactin 63, were assessed against the 
highly virulent pathogen S. aureus USA300 JE2 using a 
validated time-kill method. Thus, S. aureus USA300 JE2 grown 
to mid-exponential phase was challenged with suprainhibitory 
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concentrations (4x or 10x MIC) of 63. Vancomycin, an 
established antibiotic for treating challenging S. aureus 
infections, was used as a comparator. Viable counts (CFU/mL) 
of the bacteria were then determined at specific times over 24 h. 
A compound that reduces bacterial viability by ≥ 3 log10 CFU/mL 
is defined as bactericidal.[75]  
At 4x MIC, the [Arg(Me)10,Nle11]teixobactin 63 showed a 
greater killing rate than vancomycin in the first six hours (Figure 
5 (a)). There was, however, a regrowth of bacteria from 8 h 
onwards for compound 63. To our delight, a decrease of >3 log10 
CFU/mL was rapidly obtained with 10x MIC of 
[Arg(Me)10,Nle11]teixobactin 63, within an hour (Figure 5(b)). In 
contrast, vancomycin required up to 4 h to achieve bactericidal 
activity at 10x MIC. Thus, our lead compound 63 at 10x MIC 
showed highly efficient and sustained bactericidal activity 
against the pathogenic S. aureus USA300 JE2. 
  Vancomycin acts by binding solely to lipid II, an important 
intermediate for the synthesis of bacterial peptidoglycan.[10,76] On 
the other hand, teixobactin is reported to bind to both lipid II and 
lipid III, which may account for its remarkable bactericidal activity 
over vancomycin.[4,11] Lipid III is the precursor for the synthesis 
of wall teichoic acid (WTA) which is covalently attached to 
peptidoglycan.[77,78] It is formed by the TarO-mediated 
attachment of N-acetylglucosamine to undecaprenyl 
pyrophosphate. Subsequently, N-acetylmannosamine is 
transferred to lipid III by TarA. The resultant lipid-linked 
disaccharide intermediate is then modified by a series of other 
Tar enzymes before being transported through the cell 
membrane to be linked to the peptidoglycan network.[77,79,80] 
Paradoxically, the deletion of genes encoding TarO and/or TarA 
has no effects on the in vitro viability of bacteria. These early-
stage enzymes have been deemed non-essential and are useful 
for studying potential WTA inhibitors.[80–83]  
Under normal circumstances, WTA plays a pivotal role in 
anchoring the major autolysin Atl to prevent unregulated self-
digestion. The absence of WTA results in the delocalisation of 
this enzyme throughout the cell surface that eventually leads to 
bacterial lysis.[84,85] It is anticipated that the rapid bactericidal 
activity of [Arg(Me)10,Nle11]teixobactin 63 might also be due to 
the synergistic inhibition of both peptidoglycan and WTA 
synthesis.  
To demonstrate the significance of WTA for bacterial 
survival, we determined the killing kinetics of both 
[Arg(Me)10,Nle11]teixobactin and vancomycin (4x MIC) in the 
presence of sub-lethal tunicamycin (0.05x MIC), a highly 
selective inhibitor of TarO[86]. At the sub-MIC concentration, 
tunicamycin showed no effects on cell viability and growth of S. 
aureus USA300 JE2 (Figure 5(a)), though it is predicted that 
WTA production is substantially suppressed. In the initial eight 
hours, the bactericidal profile was very similar for vancomycin 
regardless of the presence of tunicamycin. However, the viable 
count was reduced to a greater extent (<0.1 log10 CFU/mL) at 24 
h when vancomycin was used with tunicamycin compared to 
vancomycin alone (ca. 1 log10 CFU/mL remaining). Tunicamycin 
also enhanced the killing activity of 4x MIC 
[Arg(Me)10,Nle11]teixobactin 63 since there was no regrowth of 
bacteria throughout the 24 h (Figure 5(a)). This suggests that 
compound 63 and tunicamycin are likely to perturb different 
stages of the WTA biosynthesis. The rapid killing activity of 63 
could therefore be due to a more lethal target within the WTA 
biosynthetic pathway and further work is required to establish its 
target. Despite being viable in vitro, bacterial cells without WTA 
tend to show an altered morphology and defects in cellular 
division.[83,86] This may explain why the killing effects of both 
vancomycin and 63 were noticeably potentiated when used in 
combination with tunicamycin.  
The time-kill assay was similarly conducted on P. acnes 
ATCC 11828. As expected, [Arg(Me)10,Nle11]teixobactin 63 was 
bactericidal and exhibited a faster killing rate than vancomycin 
(Figure 6). Unlike in S. aureus, however, no regrowth of bacteria 
was observed up to 48 h with 4x MIC of compound 63. Once 
again, this confirms our analogue 63 holds great promise for the 
treatment of P. acnes infection.  
 
Figure 6. Time-kill curves of P. acnes ATCC 11828 treated with 4x MIC 
[Arg(Me)10,Nle11]teixobactin 63 or 4x MIC vancomycin. Data are presented as 
the mean log10 viable count (CFU/mL) ± SD of two independent experiments.  
 
Checkerboard assay to determine antimicrobial effect of 
teixobactin analogues-colistin combination against P. 
aeruginosa 
 
Given the size (M.W. 1200–1300) and hydrophobic nature of the 
teixobactin analogues reported herein, it is not surprising that 
these compounds failed to display effective antimicrobial activity 
against the Gram-negative pathogen, Pseudomonas aeruginosa 
(MIC >256 μg/mL, Table 3). The bacterial outer membrane 
presents a significant permeability barrier[87] and hence, the 
teixobactin analogues are unable to reach their molecular target, 
i.e. lipid II, that is located in the periplasm; lipid III and teichoic 
acid are not found in Gram-negatives. The Gram-negative outer 
membrane is an asymmetric bilayer comprised of 
lipopolysaccharides (lipid A and O-antigen moieties) and 
glycerophospholipids. Colistin, a cationic polymyxin antibiotic, is 
known to disrupt Gram-negative outer membrane via its 
interactions with anionic lipopolysaccharides and 
phospholipids.[88] Thus, we hypothesized that the membrane 
disruptive capability of colistin would enable permeation of 
teixobactin analogues through the pseudomonal outer 
membrane and hence ‘restore’ antimicrobial susceptibility.  
Indeed, growth inhibition was observed when several of 
the analogues were tested in combination with 0.5x MIC colistin 
against P. aeruginosa PAO1 (Figure 7). In fact, the MIC values 
of (Arg10,Nle11)teixobactin 57 and (Tfn10,Nle11)teixobactin 66 
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were markedly reduced from >256 μg/mL to 64 μg/mL and 32 
µg/mL, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Antimicrobial susceptibility testing of analogues (Arg10)teixobactin 55, 
(Lys10)teixobactin 56, (Arg10,Nle11)teixobactin 57, (Arg10,Nva11)teixobactin 58, 
(ADMA10,Nle11)teixobactin 64, (SDMA10,Nle11)teixobactin 65 and (Tfn10,Nle11)-
teixobactin 66 in combination with colistin (2 μg/mL, 0.5x MIC) against P. 
aeruginosa PAO1. Wells A2–A8 and wells B2–B8 were set up as control wells 
containing colistin at 4 μg/mL and 2 μg/mL respectively. +ve = media and 
bacteria only, -ve = media only.  
 
In order to comprehensively establish a synergistic or 
additive effect of the test compounds-colistin combination, an 
antimicrobial checkerboard assay against P. aeruginosa PAO1 
was performed on analogue 66 and our lead compound 
[Arg(Me)10,Nle11]teixobactin 63 (Figure 8); the results for 
analogue 57 and the comparator antibiotic vancomycin can be 
found in Supporting Information (Figure S1, p. S36). Surprisingly, 
despite its high potency against the tested Gram-positive 
pathogens, compound 63 remained inactive at 256 μg/mL even 
when combined with colistin (Figure 8(b)). The vancomycin (256 
µg/mL)-colistin (0.125–0.5x MIC) combinations were similarly 
found to be ineffective. In sharp contrast, when 
(Tfn10,Nle11)teixobactin 66 was used in combination with colistin, 
an additive effect (FICI = 0.63) was observed in the 
checkerboard assay against P. aeruginosa PAO1 (Figure 8(a)).  
Multidrug resistant (MDR) P. aeruginosa is increasingly 
responsible for infection in the critically ill patients. In many of 
these cases, colistin is used as the last resort treatment option. 
However, the use of high doses of colistin is limited by its 
nephrotoxicity.[88] The pronounced restoration of antimicrobial 
susceptibility of (Tfn10,Nle11)teixobactin 66 by sub-MIC level of 
colistin offers, for the first time, an unique therapeutic option for 
the treatment of infections caused by MDR P. aeruginosa and 
possibly other Gram-negative pathogens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Checkerboard assay of (a) (Tfn10,Nle11)teixobactin 66 and (b) 
[Arg(Me)10,Nle11]teixobactin 63 with varying concentration of colistin. +ve = 
media and bacteria only, -ve = media only.  
Conclusions 
In summary, a series of 14 unique teixobactin analogues have 
been designed and synthesized to critically examine the roles of 
the residues at positions 9, 10 and 11 within the macrocyclic 
structure.  The antimicrobial activity of the analogues was 
determined against a panel of clinically important S. aureus 
isolates, including the highly virulent USA300 JE2 and Mu50 (a 
vancomycin intermediate-resistant S. aureus, VISA) strains. The 
teixobactin analogues were also tested against a panel of P. 
acnes strains and they were found to be more potent than 
against S. aureus. The in vitro antimicrobial effect of these 
analogues provided valuable SARs information and 
[Arg(Me)10,Nle11]teixobactin 63 (IC50 = 3.84 ± 0.26 μM against S. 
aureus SH1000; MIC 2–4 μg/mL against 5 different S. aureus 
strains and 3 different P. acnes strains) has been identified as a 
lead candidate. The impressive bactericidal activity 
(characterised by the rate of kill) of compound 63 at 10x MIC, 
exceeding that of vancomycin, further reinforces its therapeutic 
potential. Importantly, when used in combination with an outer 
(a) 
(b) 
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membrane-disruptive antibiotic, colistin at 0.5x MIC, the 
antimicrobial activity of a subset of teixobactin analogues 
against P. aeruginosa was ‘restored’, thereby providing a 
potential option for the treatment of infections caused by MDR P. 
aeruginosa and possibly other Gram-negative pathogens. In 
light of the pronounced antimicrobial effectiveness of the 
[Tfn10,Nle11]teixobactin 66 (32 μg/mL)-colistin (2 μg/mL; 0.5x 
MIC) combination, its potency should be determined against a 
wider spectrum of clinical isolates of not only P. aeruginosa but 
also MDR Acinetobacter baumannii and Klebsiella pneumoniae. 
Furthermore, the antibiotic combination should be evaluated 
against colistin-resistant Gram-negatives. These future studies 
will be reported in due course. 
 
Experimental section 
 
For full experimental procedures, spectroscopic and analytical 
data for all new compounds, including copies of NMR spectra, 
see the Supporting Information.  
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